Bibliographic Details
| Title: |
Effect of fluvoxamine on plasma interleukin-6 in patients with major depressive disorder: a prospective follow-up study |
| Authors: |
Xueqin Li, Danfeng Yan, Mei Liao, Li Zhang, ZeXuan Li, Bangshan Liu, Yanjun Chen, Yan Zhang, Jin Liu, LingJiang Li |
| Source: |
Frontiers in Psychiatry, Vol 14 (2023) |
| Publisher Information: |
Frontiers Media S.A., 2023. |
| Publication Year: |
2023 |
| Collection: |
LCC:Psychiatry |
| Subject Terms: |
major depressive disorder, fluvoxamine, interleukin-6, antidepressant, prospective follow-up study, Psychiatry, RC435-571 |
| More Details: |
IntroductionMajor depressive disorder (MDD) is associated with low-grade inflammation, and anti-inflammatory treatment can help improve depressive symptoms. A recent study found that fluvoxamine (FLV) can reduce Interleukin-6 (IL-6) production via sigma-1 receptor in inflammation models. However, the anti- IL-6 effect of FLV in treating patients with MDD and whether it can contribute to antidepressant effects remain unclear.MethodsA total of 65 patients with MDD and 34 healthy controls were recruited at baseline, and 50 patients completed the FLV treatment for 2 months. We assessed depression and anhedonia and collected plasma IL-6 levels at baseline, 1 month, and 2 months after baseline. This study evaluated the changes in clinical measures and IL-6 during treatment and analyzed their association. Further subgroup analyses were conducted in patients with MDD with high, medium, or low IL-6.ResultsDepression and anhedonia were significantly improved in patients with MDD, while the IL-6 did not significantly change after the FLV treatment. However, IL-6 significantly declined after the FLV treatment among patients with MDD with higher baseline IL-6. No significant associations were found between the changes in depressive symptoms and IL-6.ConclusionOur study provided preliminary evidence suggesting that the anti-IL-6 effect of FLV might not play a vital role in its antidepressant treatment, at least in patients with MDD with low inflammation. However, for patients with MDD with higher IL-6, FLV can help reduce IL-6 significantly in the antidepressant treatment, which may help guide the individual treatment of MDD with higher IL-6 levels.Clinical trial registrationhttps://clinicaltrials.gov/ct2/show/NCT04160377, identifier NCT04160377. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
1664-0640 |
| Relation: |
https://www.frontiersin.org/articles/10.3389/fpsyt.2023.1163754/full; https://doaj.org/toc/1664-0640 |
| DOI: |
10.3389/fpsyt.2023.1163754 |
| Access URL: |
https://doaj.org/article/abad36ebcad54e72a0b5a38057346652 |
| Accession Number: |
edsdoj.bad36ebcad54e72a0b5a38057346652 |
| Database: |
Directory of Open Access Journals |
